Systemic Inflammatory Indexes as Easy-to-Use Markers for Monitoring Psoriasis and Hidradenitis Suppurativa
DOI:
https://doi.org/10.2340/actadv.v106.43695Keywords:
Psoriasis, Hidradenitis Suppurativa, Systemic Immune-Inflammation Index (SII), Neutrophil-to-Lymphocyte Ratio (NLR), Systemic Inflammation Response Index (SIRI), Biologic TherapyDownloads
References
Ziehfreund S, Wecker H, Mittag S, Weis J, Tizek L,Verkhoturova V, et al. Happiness across the borders: a cross-sectional study among patients with psoriasis and atopic dermatitis in Europe. J Eur Acad Dermatol Venereol 2025; 39: 529–542 DOI: https://doi.org/10.1111/jdv.20288
Licata G, Di Brizzi EV, Castelli F, Giuffrida G, Stroppiana E, Dattola A, et al. Tildrakizumab and quality of life: deep dive into the impact of psoriasis and treatment on different domains: should psychosocial life impairment be -considered a comorbidity? J Clin Med 2025; 14: 223 DOI: https://doi.org/10.3390/jcm14010223
Zouboulis CC, Del Marmol V, Mrowietz U, Prens EP, Tzellos T, Jemec GB. Hidradenitis suppurativa/acne inversa: criteria for diagnosis, severity assessment, classification and disease evaluation. Dermatology 2015; 231: 184–190 DOI: https://doi.org/10.1159/000431175
Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 2013; 133: 377–385 DOI: https://doi.org/10.1038/jid.2012.339
Di Brizzi EV, Buononato D, Benvenuto P, et al. Effectiveness and safety after a switch to tildrakizumab: a real world multicenter Italian study in psoriasis. Dermatol Pract Concept 2023; 13: e2023215 DOI: https://doi.org/10.5826/dpc.1304a215
Mattei PL, Corey KC, Kimball AB. Psoriasis Area Severity -Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies. J Eur Acad Dermatol Venereol 2014; 28: 333–337 DOI: https://doi.org/10.1111/jdv.12106
Morariu SH, Cotoi OS, Tiucă OM, Baican A, Gheucă-Solovăstru L, Decean H, et al. Blood-count-derived inflammatory markers as predictors of response to biologics and small-molecule inhibitors in psoriasis: a multicenter study. J Clin Med 2024; 13: 3992 DOI: https://doi.org/10.3390/jcm13143992
Ding Q, Li X, Lin L, Xie X, Jing W, Chen X, et al. Association between systemic immunity-inflammation index and psoriasis among outpatient US adults. Front Immunol 2024; 15: 1368727 DOI: https://doi.org/10.3389/fimmu.2024.1368727
Satis S. New Inflammatory marker associated with disease activity in rheumatoid arthritis: the systemic immune-inflammation index. Curr Health Sci J 2021; 47: 553–557.
Utlu Z. Evaluation of systemic immune and inflammatory biomarkers in hidradenitis suppurativa. Eur Rev Med Pharmacol Sci 2023; 27: 9267–9272.
Tiucă OM, Morariu SH, Mariean CR, Tiucă RA, Nicolescu AC, Cotoi OS. Impact of blood-count-derived inflammatory markers in psoriatic disease progression. Life (Basel) 2024; 14: 114 DOI: https://doi.org/10.3390/life14010114
Kulakli S, Oguz ID, Aksan B. Could blood cell-based -inflammatory markers be used to monitor response to biologic therapy in psoriasis? Sisli Etfal Hastan Tip Bul 2023; 57: 536–542 DOI: https://doi.org/10.14744/SEMB.2023.43569
Hayran Y, Şen O, Aktaş A. Systemic Immune-Inflammation Index (SII) correlates with disease severity in hidradenitis suppurativa patients. Indian J Dermatol 2023; 68: 208–209 DOI: https://doi.org/10.4103/ijd.ijd_532_22
Kearney N, McCourt C, Hughes R, Alsharqi A, O’Kane D, Kirby B. Systemic immune inflammation index is a -marker of cardiovascular risk and not just disease -severity in hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2022; 36: e928–e929 DOI: https://doi.org/10.1111/jdv.18322
Zhao Y, Bai YP, Li LF. Association between systemic immune-inflammation index and psoriasis, psoriasis comorbidities, and all-cause mortality: a study based on NHANES. Immun Inflamm Dis 2024; 12: e70050 DOI: https://doi.org/10.1002/iid3.70050
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2026 Eugenia Veronica Di Brizzi, Dario Buononato, Alfonso Luca Falco, Elisabetta Fulgione, Stefano Caccavale, Giuseppe Argenziano, Anna Balato
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
